1 / 16

The I nvestigation of the M anagement of P er i carditis

The I nvestigation of the M anagement of P er i carditis. The IMPI Trial (‘ ee-MP-ee ’ means Warriors in Zulu). Duality of interests. B.M. Mayosi has received research grants from AstraZeneca, Cadila Pharma, Novartis, Pfizer, Roche, and Servier. Background.

mircea
Download Presentation

The I nvestigation of the M anagement of P er i carditis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Investigation of the Management of Pericarditis The IMPI Trial (‘ee-MP-ee’ means Warriors in Zulu)

  2. Duality of interests B.M. Mayosi has received research grants from AstraZeneca, Cadila Pharma, Novartis, Pfizer, Roche, and Servier

  3. Background • Tuberculous (TB) pericarditis affects a million people per year. • The case fatality rate is 26% despite anti-TB treatment. • Hypotheses: • Anti-inflammatory effect of Steroids may reduce morbidity (i.e., cardiac tamponade and constrictive pericarditis) and mortality in TB pericarditis. • Immunotherapy with Mycobacterium indicus pranii (Mw), a non-pathogenic environmental organism, may enhance cure of TB. • However, the effectiveness and safety of Steroids and Mwin TB pericarditis in uncertain.

  4. IMPI: Primary Objectives To assess the effect of Prednisolone and Mw in definite or probable TB pericardial effusion on: • The composite outcome of death, cardiac tamponade requiring pericardiocentesis, or constrictive pericarditis; • The incidence of opportunistic infection and malignancy.

  5. IMPI Trial: Study Design PATIENTS WITH DEFINITE OR PROBABLETUBERCULOUS PERICARDIAL EFFUSION RANDOMIZATION PREDNISOLONE X 6 weeks PLACEBO X 6 weeks M. w X 5 Doses Placebo X 5 Doses M. w X 5 Doses Placebo X 5 Doses Follow-up data at hospital discharge, at weeks 2, 4 and 6, and months 3, 6 and thereafter 6 monthly for 2 years, and annually up to 4 years

  6. IMPI: Trial Interventions • Prednisolone or placebo • 120 mg/day in 1st wk, followed by 90 mg/day in 2nd wk, 60 mg/day in 3rdwk, 30 mg/day in 4thwk, 15 mg/day in 5thwk, and 5 mg/day in 6th wk. • M. winjection orplacebo • 5 doses of 0.1 ml intradermal injection at enrolment, then 2 wks, 4 wks, 6 wks, and 3 mo.

  7. IMPI: Organization 19 centres, 8 countries African Coordinating Center University of Cape Town South Africa International Coordinating Center Population Health Research Institute HHS and McMaster University, Hamilton, Canada Sponsors: Canadian Institutes for Health Research, Cadila Pharma, South African Medical Research Council, Lily and Ernst Hausmann Trust

  8. IMPI: Target Population • Inclusion Criteria • Age ≥ 18 years • Pericardial effusion on echocardiography • Evidence of definite or probable TB pericarditis • Within 1 week of starting of anti-TB treatment • Exclusion Criteria • Presence of an alternative cause of pericardial disease • Pregnancy • Use of corticosteroids in the previous month • Allergy to the M. indicus pranii

  9. IMPI : Baseline Characteristics

  10. IMPI Prednisolone: Time To Constriction

  11. IMPI Prednisolone: Hospitalization

  12. IMPI: Time To Malignancy

  13. IMPI: Conclusions In those with definite or probable TB pericardial effusion: • Prednisolone for 6 weeks and M.wfor three months had no significant effect on the combined outcome of death from all causes, cardiac tamponade requiring pericardiocentesis or constrictive pericarditis. • Both therapies were associated with an increased risk of HIV-associated malignancy. • However, use of prednisolone reduced the incidence of constrictive pericarditis and hospitalization. • The beneficial effects of prednisolone on constriction and hospitalization were similar in HIV-positive and HIV-negative patients.

More Related